Germany's IQWiG backs Bristol-Myers' Opdivo in melanoma; Pfizer ALL med inotuzumab gets 'breakthrough' status;

> German cost-effectiveness gatekeepers decided that Bristol-Myers Squibb's ($BMY) immuno-oncology treatment Opdivo offers an "added benefit" over previous treatments, particularly in men. Report

> Pfizer ($PFE) scored the FDA's breakthrough therapy designation on inotuzumab, its experimental drug for acute lymphoblastic leukemia, the third of Pfizer's cancer candidates to win that status. Report

> Allergan ($AGN) expanded its portfolio of dry-eye remedies with the launch of the over-the-counter Refresh Optive Gel Drops. Release

> LEO Pharma won FDA approval for Enstilar, its topical foam treatment for psoriasis vulgaris in patients 18 and older. Report

And Finally... Novartis' ($NVS) new affordable-drugs scheme for emerging markets launched in Kenya. Release

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.